glp 1 beta cell GLP-1: Actions on Beta-cell Mass and Function Figure 4 from Two incretin
Description
With Semaglutide patents expiring in 2026, Indian pharma has a chance to lead the GLP-1 drug market.

The MHRA has updated its GLP-1 guidance due to a risk of the rare occurence of NAION among semaglutide patients

The wild card-to-uncertainty about GLP-1 meds growth will be reimbursement: spending will continue to accelerate with upside if more widely reimbursed, IQVIA projects

For Pharma: Could introduce additional competitive pressure on branded manufacturers like Novo Nordisk and Eli Lilly, encouraging continued innovation

4x Lemon Original
This is about reality